<SEC-DOCUMENT>0001847903-23-000029.txt : 20230113
<SEC-HEADER>0001847903-23-000029.hdr.sgml : 20230113
<ACCEPTANCE-DATETIME>20230113174624
ACCESSION NUMBER:		0001847903-23-000029
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20230113
DATE AS OF CHANGE:		20230113

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GRAINGER DAVID J
		CENTRAL INDEX KEY:			0001887115

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40445
		FILM NUMBER:		23529788

	MAIL ADDRESS:	
		STREET 1:		C/O CENTESSA PHARMACEUTICALS PLC
		STREET 2:		3RD FL., 1 ASHLEY RD, ALTRINCHAM
		CITY:			CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		44 7391 789784

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wf-form4_167364997060589.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-09-30</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001847903</issuerCik>
        <issuerName>Centessa Pharmaceuticals plc</issuerName>
        <issuerTradingSymbol>CNTA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001887115</rptOwnerCik>
            <rptOwnerName>GRAINGER DAVID J</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CENTESSA PHARMACEUTICALS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>3RD FL., 1 ASHLEY RD, ALTRINCHAM</rptOwnerStreet2>
            <rptOwnerCity>CHESHIRE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>WA14 2DT</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Innovation Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2022-09-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>7154</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.25</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>906602</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>27500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F5"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
        <footnote id="F2">Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.</footnote>
        <footnote id="F3">Shares held by the Reporting Person after the reported transaction herein and does not include shares acquired or disposed of in subsequent reported transactions after September 30, 2022.</footnote>
        <footnote id="F4">As of year end December 31, 2022, the Reporting Person held 904,105 shares directly.</footnote>
        <footnote id="F5">Held by RxCelerate Limited (&quot;RxCelerate&quot;). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Gregory Weinhoff, attorney-in-fact</signatureName>
        <signatureDate>2023-01-13</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
